Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 in Advanced Solid Tumors
NCT04868344Phase 1Completed
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- May 2018
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of becotatug vedotin in solid tumor, colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC) and 1 more, sponsored by Lepu Biopharma Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 21 days and Objective Response Rate at 24 weeks. Started May 2018; status: completed.
02
Drugs
becotatug vedotin
03
Conditions
solid tumorcolorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04868344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868344.